AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17080448
Drug: Treatment modeling
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment modeling
Trial: 15631318
Drug: omeprazole and
RxNorm normalized name: Omeprazole and Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: omeprazole and amoxicillin (OA)
Trial: 15631318
Drug: omeprazole, amoxicillin
RxNorm normalized name: omeprazole, amoxicillin and rifabutin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omeprazole, amoxicillin and tinidazole (OAT)
Trial: 11414346
Drug: Random treatment
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Random treatment assignment
Trial: 9715740
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (10 g day-1)
Trial: 7839282
Drug: Intramuscular magnesium
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular magnesium sulphate regimen (loading dose of 14 g: 4 g i.v. and 10 g IM, followed by 5 g 4-hourly)
Trial: 7839282
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulphate regimen (loading dose of 6 g i.v., followed by maintenance infusion of 2 g/h)
Trial: 3402353
Drug: Urapidil 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urapidil 25 mg intravenously
Trial: 30561313
Drug: Cotrimoxazole preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotrimoxazole preventive therapy
Trial: 30561313
Drug: Antibacterial drugs
RxNorm normalized name: Dermoplast Antibacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibacterial drugs (general)
Trial: 28097295
Drug: Systemic β-blocker
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic β-blocker use
Trial: 25730540
Drug: Water-soluble polyantimicrobial
RxNorm normalized name: WATER SOLUBLE BASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water-soluble polyantimicrobial gel (BWG)
Trial: 20656508
Drug: Actual weight-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Actual weight-based dose of IV t-PA (administered dose divided by actual weight, capped at 100 kg)
Trial: 20656508
Drug: Actual weight-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Actual weight-based dose of IV t-PA
Trial: 17299064
Drug: Pio (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pio (7.5 mg/d) + Flu (62.5 mg/d) + Met (850 mg/d) + transdermal estroprogestagen
Trial: 17299064
Drug: Flu (62.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flu (62.5 mg/d) + Met (850 mg/d) + transdermal estroprogestagen
Trial: 15159232
Drug: WB (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WB (12 g fiber/d)
Trial: 15159232
Drug: WBRS (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WBRS (12 g WB fiber/d plus 22 g RS/d)
Trial: 12743147
Drug: Supportive-expressive (SE)
RxNorm normalized name: Selenomethionine Se-75
DrugBank: Selenomethionine Se-75 (DB09400)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive-expressive (SE) therapy group
Trial: 12743147
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (SE therapy and control)
Trial: 10426704
Drug: High-vegetable diet
RxNorm normalized name: Hydrogenated Vegetable Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-vegetable diet (490 g/d)
Trial: 10426704
Drug: Low-vegetable diet
RxNorm normalized name: Hydrogenated Vegetable Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-vegetable diet supplemented with beta-carotene (6 mg/d) and lutein (9 mg/d)
Trial: 10426704
Drug: Low-vegetable diet
RxNorm normalized name: Hydrogenated Vegetable Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-vegetable diet (130 g/d)
Trial: 7750429
Drug: Potassium citrate
RxNorm normalized name: Potassium Citrate
DrugBank: Potassium (DB14500)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Potassium citrate (120 mmol daily for 8 weeks)
Trial: 7750429
Drug: Potassium chloride
RxNorm normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Potassium chloride (120 mmol daily for 8 weeks)
Trial: 2180461
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg once daily (n = 41)
Trial: 2180461
Drug: Cimetidine 800
RxNorm normalized name: cimetidine 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 800 mg nocte (n = 38)
Trial: 24471979
Drug: MAL-PDT treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAL-PDT treatment
Trial: 22902599
Drug: Pregabalin 150
RxNorm normalized name: pregabalin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 150 mg 8-hourly starting the afternoon before surgery until the fifth postoperative day
Trial: 16297748
Drug: Combined sciatic
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined sciatic and femoral nerve blocks with 40 mL of 0.375% bupivacaine
Trial: 12239138
Drug: Epoetin (subcutaneous,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoetin (subcutaneous, 150 U/kg thrice weekly for a minimum of 4 weeks)
Trial: 12239138
Drug: Epoetin (weekly,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoetin (weekly, 40,000 U/wk)
Trial: 12239138
Drug: Epoetin (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoetin (dose escalation if no response)
Trial: 12239138
Drug: Epoetin (titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoetin (titration once Hgb reaches 12 g/dL)
Trial: 12239138
Drug: Epoetin for
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoetin for patients with anemia associated with low-risk myelodysplasia not receiving chemotherapy
Trial: 12239138
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy for anemic patients with hematologic malignancies
Trial: 30908627
Drug: Attachment-based family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attachment-based family therapy therapist interventions (relational reframes and focus on primary adaptive emotions)
Trial: 30908627
Drug: Attachment-based family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attachment-based family therapy therapist interventions (interpretations, reassurances, and focus on rejecting anger toward parents)
Trial: 30908627
Drug: Attachment-based family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attachment-based family therapy therapist interventions (general encouragement of affect and focus on unmet attachment/identity needs)
Trial: 27586686
Drug: Weekly diary
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly diary
Trial: 24095239
Drug: Injection technique
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection technique with traction
Trial: 24095239
Drug: Injection technique
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection technique without traction
Trial: 9491842
Drug: High vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High vancomycin trough serum levels (> 15 microg/mL)
Trial: 9491842
Drug: Low vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low vancomycin trough serum levels (< 15 microg/mL)
Trial: 30317420
Drug: 5% sodium
RxNorm normalized name: Dextrose 5% and 0.45% Sodium Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% sodium hypochlorite as a haemostatic agent
Trial: 24054874
Drug: Lactobacillus acidophilus
RxNorm normalized name: Lactobacillus acidophilus
DrugBank: Lactobacillus acidophilus (DB15823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus acidophilus (1.0×10(8) CFU, twice daily)
Trial: 24054874
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule (twice daily)
Trial: 16609107
Drug: Laser-assisted anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser-assisted anesthesia (Er:YAG unit, fluence 3.5 J/cm2, pulse width 600 microseconds, spot diameter 6 mm) with lidocaine 4% cream
Trial: 16609107
Drug: Sham laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham laser with lidocaine 4% cream
Trial: 10826853
Drug: tPA (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tPA (0.25 mg/kg/day in 0.9% saline) for 3 days
Trial: 1321186
Drug: Candoxatril 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candoxatril 200 mg twice daily
Trial: 29969907
Drug: Citalopram for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram for the treatment of agitation
Trial: 25675290
Drug: Oral cefuroxime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cefuroxime axetil 500 mg dose, twice daily for 3 days
Trial: 25675290
Drug: Parenteral cefuroxime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral cefuroxime axetil 750 mg IV dose, single dose before placement
Trial: 24680330
Drug: Systemic application
RxNorm normalized name: Vaginal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic application of dexamethasone (DEX) 10 mg×3 d followed by 5 mg×4 d
Trial: 24680330
Drug: Topical injection
RxNorm normalized name: LIDOCAINE HYDROCHLORIDE 40 mg in 1 mL TOPICAL INJECTION, SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical injection of methylprednisolone sodium succinate 40 mg every three days
Trial: 24680330
Drug: Local corticosteroids
RxNorm normalized name: Corticosteroids acting locally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local corticosteroids injection in low‐middle frequencies
Trial: 18165444
Drug: Enteral glutamine
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteral glutamine 0.5 g/kg/d during the first 24 hours of resuscitation and 10 days thereafter
Trial: 15242433
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (ITM) 20 micrograms/kg
Trial: 7962302
Drug: L-692,429 (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-692,429 (0.2 mg/kg)
Trial: 7962302
Drug: L-692,429 (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-692,429 (0.75 mg/kg)
Trial: 2853764
Drug: metoprolol +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metoprolol + terbutaline (10 mg/day + 200 mg/day)
Trial: 2853764
Drug: metoprolol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metoprolol (200 mg/day)
Trial: 2853764
Drug: terbutaline (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: terbutaline (10 mg/day)
Trial: 2853764
Drug: orciprenaline (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orciprenaline (30 mg/day)
Trial: 26657184
Drug: CMV glycoprotein
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMV glycoprotein B (gB) vaccine with MF59
Trial: 20052549
Drug: Spinach preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinach preparation
Trial: 20052549
Drug: Perilla preparation
RxNorm normalized name: PERILLA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perilla preparation
Trial: 18780315
Drug: Cisplatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (20 mg/m²/day, Days 1-5) and Vinorelbine (6 mg/m² bolus on Day 1 and 6 mg/m²/day continuous infusion on Days 1-5) with concurrent 30-gray fractionated external-beam radiotherapy
Trial: 18780315
Drug: Cisplatin and
RxNorm normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin and Vinorelbine with concurrent radiotherapy
Trial: 15911360
Drug: Adjunctive lamotrigine
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjunctive lamotrigine therapy for 16 weeks
Trial: 15911360
Drug: Lamotrigine monotherapy
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lamotrigine monotherapy for 12 weeks
Trial: 12769163
Drug: Indapamide SR
RxNorm normalized name: Indapamide
DrugBank: Indapamide (DB00808)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indapamide SR 1.5 mg once a day
Trial: 12769163
Drug: Enalapril 10
RxNorm normalized name: enalapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 10 mg once a day
Trial: 12769163
Drug: Amlodipine 5-10
RxNorm normalized name: amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5-10 mg (1st step)
Trial: 12769163
Drug: Atenolol 50-100
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50-100 mg (2nd step)
Trial: 10654588
Drug: Phytosterol ester-enriched
RxNorm normalized name: phytosterol esters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytosterol ester-enriched margarine (8.6 g vegetable oil phytosterols)
Trial: 1650023
Drug: Rapid Infusion
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid Infusion System (RIS)
Trial: 1650023
Drug: Conventional Fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Fluid Administration (CFA)
Trial: 6849742
Drug: Practolol 50
RxNorm normalized name: (±)-practolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Practolol 50 mg
Trial: 30621276
Drug: L-Valine 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Valine 0.15 kcal/min (total: 3.3 g)
Trial: 30621276
Drug: L-Valine 0.45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Valine 0.45 kcal/min (total: 9.9 g)
Trial: 28881472
Drug: Domagrozumab 10
RxNorm normalized name: Domagrozumab
DrugBank: Domagrozumab (DB15083)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domagrozumab 10 mg/kg IV (single dose)
Trial: 28881472
Drug: Domagrozumab 10
RxNorm normalized name: Domagrozumab
DrugBank: Domagrozumab (DB15083)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domagrozumab 10 mg/kg IV (multiple doses)
Trial: 28881472
Drug: Domagrozumab (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domagrozumab (various doses IV and SC)
Trial: 28881472
Drug: Domagrozumab (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domagrozumab (various doses)
Trial: 28881472
Drug: Domagrozumab 20
RxNorm normalized name: Domagrozumab
DrugBank: Domagrozumab (DB15083)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domagrozumab 20 mg/kg IV
Trial: 26847437
Drug: Sputum-based markers
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sputum-based markers of speed of clearance of bacilli (time to smear negative status, time to culture negative status on LJ or in MGIT, daily rate of change of log10(TTP) to day 56)
Trial: 25888092
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg pethidine i.v.
Trial: 23094932
Drug: Supportive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive treatment for the same time period
Trial: 12453973
Drug: Inhaled regular
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled regular insulin (INH) via Aerodose Insulin Inhaler, 240 units
Trial: 12453973
Drug: Inhaled regular
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled regular insulin (INH)
Trial: 12453973
Drug: Subcutaneously injected
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneously injected regular insulin (SC)
Trial: 30646314
Drug: Levocarnitine (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocarnitine (18 g)
Trial: 30646314
Drug: Levocarnitine (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocarnitine (12 g)
Trial: 30646314
Drug: Levocarnitine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocarnitine (6 g)
Trial: 24498404
Drug: School-based physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: School-based physical activity program (KISS) including daily physical education (two additional lessons per week), short physical activity breaks, and daily physical activity homework.
Trial: 21945258
Drug: 15 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 μg of hemagglutinin antigen without adjuvant
Trial: 21945258
Drug: 7.5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 μg of hemagglutinin antigen with aluminum hydroxide, MPL and squalene
Trial: 21945258
Drug: 3.75 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 μg of hemagglutinin antigen with aluminum hydroxide and MPL
Trial: 21945258
Drug: 3.75 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 μg of hemagglutinin antigen with aluminum hydroxide and squalene
Trial: 11896424
Drug: Cyclophosphamide (CPM)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (CPM) 5 g/m(2)
Trial: 11896424
Drug: Overall mobilization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall mobilization chemotherapy regimens (DHAP or CPM)
Trial: 9588637
Drug: Salbutamol via
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol via pressurised metered dose inhaler (PMDI)
Trial: 20356487
Drug: Moxifloxacin-based triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin-based triple therapy (rabeprazole 10 mg twice a day, moxifloxacin 400 mg/day, amoxicillin 1000 mg twice a day)
Trial: 20356487
Drug: Bismuth-based quadruple
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth-based quadruple therapy (rabeprazole 10 mg twice a day, bismuth salts 150 mg three times a day, clarithromycin 500 mg twice a day, metronidazole 400 mg twice a day)
Trial: 18055472
Drug: Abatacept (approximately
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abatacept (approximately 10 mg/kg every 4 weeks)
Trial: 18055472
Drug: Infliximab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infliximab (3 mg/kg every 8 weeks)
Trial: 16035956
Drug: Celecoxib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (400 mg/d)
Trial: 12514674
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C infusion with furosemide
Trial: 12514674
Drug: Furosemide with
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furosemide with vitamin C and kallikrein inhibitor (nafamostat mesilate)
Trial: 10826586
Drug: Local anaesthetic
RxNorm normalized name: Local anaesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anaesthetic spray
Trial: 6541512
Drug: Conventional enteric-coated
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional enteric-coated tablet (ET)
Trial: 6541512
Drug: Conventional aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional aspirin (control)
Trial: 29948188
Drug: Selective serotonin
RxNorm normalized name: Selective serotonin (5HT1) agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective serotonin reuptake inhibitor (escitalopram)
Trial: 25181575
Drug: 1000 μg
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 μg of phylloquinone daily for 12 months (with Ca 500 mg/d and vitamin D3 10 μg/d)
Trial: 25181575
Drug: Placebo (with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (with Ca 500 mg/d and vitamin D3 10 μg/d)
Trial: 23700589
Drug: Traditional text-/image-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional text-/image-based learning supplements
Trial: 17963865
Drug: Diaphragm with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diaphragm with 6% CS gel
Trial: 17963865
Drug: Diaphragm with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diaphragm with KY gel
Trial: 17963865
Drug: CS gel
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS gel alone
Trial: 11983451
Drug: Daily interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily interferon alfa-2b (3 million units per day for 12 weeks then 3 million units three times per week for 24 weeks) and ribavirin (36 week treatment)
Trial: 11983451
Drug: Interferon alfa-2b
RxNorm normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon alfa-2b three times a week (alone or in combination with ribavirin)
Trial: 9802051
Drug: Music intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Music intervention during high-dose chemotherapy (48 hours of high-dose cyclophosphamide)
Trial: 2545454
Drug: Hydrochlorothiazide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (50 mg day‐1)
Trial: 2545454
Drug: Enalapril (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (20 mg day‐1)